Buy Retatrutide Value Pack 3 x 10mg in Australia
Buy the Retatrutide value pack in Australia from Macropus Peptides: three sealed 10mg vials of research-grade lyophilised peptide, all drawn from one lot. Each vial carries its own printed label with compound, strength, lot number and storage temperature, and the certificate of analysis for that lot is sent on request. Splitting 30 milligrams across three small vials lets a laboratory reconstitute one at a time while the other two stay dry and sealed in the freezer. The pack costs slightly less per vial than buying three single Retatrutide 10mg vials, so repeat buyers of the small strength save a little on every order. Bacteriostatic water is sold separately and can join the same cart. Parcels leave our Australian premises for every state and territory. Sold to buyers aged 18 and over for in-vitro laboratory research only, never for human or animal use.
| Kit | Retatrutide value pack 3 × 10mg |
|---|---|
| Amount | 3 × 10 mg |
| Form | Research kit |
| Contents | Three Retatrutide 10mg vials |
| Category | Kits, stacks and value packs |
| Storage | See label |
| Testing | HPLC purity 98% or higher and mass spectrometry identity, every batch |
| Certificate of analysis | Available for every lot, matched to the lot number on the label |
Buy Retatrutide Value Pack Australia: 3 x 10mg Vials
Macropus Peptides sells three 10mg vials of the triple agonist as one order line, 30 milligrams of research-grade lyophilised peptide in total. All three are filled from a single lot, then sealed and labelled one by one, and the set is priced slightly below three single vials. It is built for laboratories that already work in 10 milligram portions and want two sealed reserves on the shelf without bringing a second batch into the study.
What is in the Retatrutide 3 x 10mg pack
- Three glass vials, 10 milligrams each
- Freeze-dried powder under crimped caps
- Separate labels showing lot and storage
- One lot, one certificate of analysis
Every vial holds the same compound, coded LY3437943 during development: a synthetic chain of 39 amino acids designed to switch on the GIP, GLP-1 and glucagon receptors at once. It is still an investigational molecule in phase 3 trials. Diluent, syringes and swabs are left out on purpose, so each buyer can pick the bottle size and consumables that fit the protocol.
How Retatrutide works in research: three receptors from one chain
GIP and GLP-1 are incretins, gut hormones that lift insulin output when glucose is raised. Glucagon pulls in another direction, telling the liver to release glucose and burn more fatty acids. This molecule carries all three signals, and receptor assays place its strongest activity at GIP. Unnatural amino acids near the start of the sequence shield it from DPP-4, the enzyme that clears native incretins within minutes, and a C20 fatty diacid side chain binds serum albumin to slow its clearance. Laboratories use it to separate what the glucagon arm contributes from what the incretin pair delivers, usually with single and dual agonists run as comparators.
Retatrutide clinical trials: the published record in order
The literature runs in a clear sequence. Discovery chemistry, receptor pharmacology and first human data appeared together in Cell Metabolism in 2022, and The Lancet printed a phase 1b trial in people with type 2 diabetes later that year. Two phase 2 papers arrived in 2023: an obesity trial in NEJM and a second diabetes trial, again in The Lancet. A 2024 Nature Medicine report then examined liver fat in a subgroup of the obesity trial. Those studies measured body weight, glycaemic control and hepatic fat, and they carried the compound into a phase 3 programme that has not yet reported. Designs and endpoints for each paper sit in our triple agonist research studies library.
Retatrutide value pack specifications
| Specification | Detail |
|---|---|
| Kit | Retatrutide value pack 3 × 10mg |
| Amount | 3 × 10 mg |
| Form | Research kit |
| Contents | Three Retatrutide 10mg vials |
| Category | Kits, stacks and value packs |
| Storage | See label |
Each vial holds a dry white cake under a rubber septum and aluminium crimp. The three labels print the same lot code, strength and storage line, so a single certificate of analysis applies to the whole carton and a single line in the lab register tracks all three vials.
Retatrutide price: the pack against single vials
| Option | Price |
|---|---|
| Retatrutide value pack 3 × 10mg | $469.99 |
Three single 10mg vials bought separately cost a little more than the pack, which trims roughly one fiftieth from each vial. Per milligram, that puts the pack just under the lone 10mg vial but above our 15mg, 20mg and 30mg vials, and well above the 2 x 30mg value pack, the cheapest route per milligram in the range. The case for this format is portioning rather than the lowest price: 30 milligrams held as three dry, sealed units.
Retatrutide 10mg vial one: the working stock
The first vial is the one to reconstitute. Made up with 2 mL of diluent it reaches 5 mg per mL, a practical stock for validating a method. Record its lot code and mixing date in the register, because every reading taken from it can later be set against the two vials that follow, and all three come from the same batch.
The other two vials: sealed Retatrutide reserve stock
The remaining pair stays dry and frozen at minus 20 °C until the working stock is used up or reaches the end of its in-use period. Freeze-dried peptide holds far better than peptide in solution, so keeping the reserve as powder protects it through months of work. A sealed vial can also travel to a second bench or a partner group without any liquid being transferred between containers.
Where to buy the Retatrutide value pack in Australia
- Sold online at macropuspeptides.com, priced at $469.99
- Every batch HPLC tested to 98% or higher purity, with identity confirmed by mass spectrometry
- A certificate of analysis for every lot, matched to the lot number printed on the label
- Same-day dispatch from Australian stock for orders paid before 2pm AEST on a business day
- Tracked delivery Australia wide: standard in 2 to 5 working days, express in 1 to 2 working days
- Payment by PayID or bank transfer, with your order ID as the reference
How to get Retatrutide: ordering the pack online
- Choose the 3 x 10mg pack
- Add bacteriostatic water if needed
- Add syringes and swabs separately
- Confirm adult research use at checkout
- Request the certificate for your lot
Retatrutide calculator: bac water for each 10mg vial
Concentration equals vial content divided by diluent volume, so one 10mg vial gives:
- 1 mL: 10 mg per mL
- 2 mL: 5 mg per mL
- 2.5 mL: 4 mg per mL
- 4 mL: 2.5 mg per mL
At 2 mL apiece the three vials use 6 mL between them, leaving 4 mL in a 10mL bottle of bacteriostatic water. Our peptide calculator turns any other volume into milligrams and micrograms per millilitre, and a volume validated on the first vial carries straight across to the second and third.
Is Retatrutide available in Australia
Yes, as laboratory research material and only in that form. It has no ARTG entry, the TGA has not evaluated it, and any future registration as a medicine would follow a sponsor application once phase 3 is complete. Buying three vials rather than one changes nothing about that status. Research peptides can fall within the Poisons Standard, so confirm the current schedule for your organisation before ordering.
Retatrutide for sale Australia wide: packs, kits and single vials
Every pack is dispatched from Australian stock, so parcels bound for Perth, Canberra, Hobart, Brisbane or a country town never pass through customs. Buyers who prefer one vial at a time can order the single Retatrutide vial in four strengths, while the one-vial starter kit pairs a 10mg vial with 3 mL of diluent, ten syringes and 20 swabs. Other bundles sit in peptide kits, and diluents and consumables in lab supplies.
References
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.
- Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544.
Scientific content compiled from the peer-reviewed literature above by the Macropus Peptides technical team. Information is provided for research reference only.